TRNW: A Potential Drug Target and Biomarker for Mitochondrial Function

Target Name: TRNW

NCBI ID: G4578

TRNW

Other Name(s): mitochondrially encoded tRNA tryptophan | MTTW | mitochondrially encoded tRNA-Trp (UGA/G) | MT-TW

TRNW: A Potential Drug Target and Biomarker for Mitochondrial Function

Mitochondria are organelles responsible for generating energy in the form of ATP in cells of the human body. They are also involved in the production of various molecules, including tRNA, which plays a critical role in transporting amino acids across the nuclear-cytoplasmic barrier and participating in protein synthesis. However, mitochondrial dysfunction, a condition characterized by impaired mitochondrial function, has been linked to a wide range of diseases, including cardiovascular disease, neurodegenerative diseases, and cancer. As such, identifying potential drug targets and biomarkers for mitochondrial dysfunction is of great importance for the development of new treatments for these diseases.

TRNW: A Mitochondrial Enigma

Tryptophan (Tp) is an essential amino acid that is synthesized in the cytoplasm of cells and is primarily translated into protein by the mitochondrial translation machinery. However, the mitochondrial synthesis and delivery of Tp have been proposed to be a complex process that involves several subcellular structures, including the mitochondrial cytoplasm, the mitochondrial matrix, and the endoplasmic reticulum.

Recent studies have shed light on the role of Tp in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. In addition, Tp has also been implicated in the development and progression of various diseases, including neurodegenerative diseases and cancer.

TRNW: A Potential Drug Target

One of the promising avenues for targeting mitochondrial dysfunction is the use of drugs that can modulate Tp levels or activity. TRNW, a mitochondrially encoded tRNA tryptophan, has been identified as a potential drug target for mitochondrial dysfunction due to its unique biology and subcellular localization.

TRNW is a 28 amino acid protein that is encoded by the mitochondrial gene ATP102B. It is primarily located in the mitochondrial cytoplasm and is involved in the delivery of Tp to the cytoplasm where it can be translated into protein. TRNW has been shown to play a critical role in regulating the levels of Tp in the cytoplasm and has been linked to the dysfunctional delivery of Tp in various cellular processes.

In addition, TRNW has been shown to be involved in the regulation of cellular processes that are crucial for the survival and growth of cells, including cell apoptosis, cell cycle progression, and inflammation. This suggests that modulating TRNW activity could be a promising strategy for targeting mitochondrial dysfunction and potentially treating a wide range of diseases.

TRNW: A Potential Biomarker

The dysfunctional delivery of Tp in cells can also be used as a potential biomarker for mitochondrial dysfunction. Since TRNW is involved in the delivery of Tp to the cytoplasm, changes in the level of Tp in the cytoplasm can be an indicator of impaired mitochondrial function.

Studies have shown that TRNW levels are reduced in various cellular processes that are characterized by impaired mitochondrial function, including neurodegenerative diseases and cancer. Additionally, individuals with certain genetic mutations, such as those associated with certain inherited neurodegenerative diseases, have been shown to have reduced levels of TRNW in their brain cells.

The potential use of TRNW as a biomarker for mitochondrial dysfunction could have important implications for the diagnosis and treatment of these diseases. By identifying individuals with reduced TRNW levels, researchers could potentially develop new diagnostic tests and therapeutic approaches for treating

Protein Name: Mitochondrially Encoded TRNA Tryptophan

The "TRNW Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRNW comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets